ITM

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

Retrieved on: 
Dienstag, April 23, 2024

Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that the first patient has been dosed in an investigator-initiated trial (IIT) with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.

Key Points: 
  • Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that the first patient has been dosed in an investigator-initiated trial (IIT) with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.
  • The IIT is sponsored by the University Hospital Münster, conducted in hospitals in Münster, Essen, Cologne, and Würzburg, and supported by Helmholtz Munich and ITM.
  • After glioblastoma patients receive standard treatment with surgery, radio- and chemotherapy, individual tumor cells often remain undetected in surrounding tissue and grow again leading to relapse.
  • Patients will receive their personalized calculated total doses of ITM-31 in three fractions with an interval of 4 weeks between injections.

U.S. Eagle Credit Union Announces the Opening of its New Albuquerque South Valley Branch

Retrieved on: 
Freitag, April 12, 2024

ALBUQUERQUE, N.M., April 12, 2024 /PRNewswire/ -- U.S. Eagle Federal Credit Union, one of New Mexico's leading credit unions with more than 93,000 members, announces today the opening of its new Herrera Isleta Branch to provide banking and financial services to local businesses and members living in the South Valley and Mesa Del Sol communities. The Herrera Isleta Branch is located at 3801 Isleta Blvd. SW, in southwest Albuquerque.

Key Points: 
  • ALBUQUERQUE, N.M., April 12, 2024 /PRNewswire/ -- U.S. Eagle Federal Credit Union, one of New Mexico's leading credit unions with more than 93,000 members, announces today the opening of its new Herrera Isleta Branch to provide banking and financial services to local businesses and members living in the South Valley and Mesa Del Sol communities.
  • The new branch is dedicated to the life and service of Kenneth E. Herrera, former Board Director of U.S. Eagle.
  • One of his passions was to ensure that U.S. Eagle provide the South Valley neighborhood with the financial products and services they need and deserve.
  • "We are pleased to honor the memory of Kenneth by dedicating our newest branch to him and the legacy he has left at the credit union and with our members," said Marsha Majors, president and CEO of U.S. Eagle Federal Credit Union.

MONITORAPP Strengthens Business in Japan

Retrieved on: 
Montag, März 11, 2024

MONITORAPP is a security solution vendor that offers various application security technologies around the world and has expanded its range of services to accelerate and simplify access to cloud solutions.

Key Points: 
  • MONITORAPP is a security solution vendor that offers various application security technologies around the world and has expanded its range of services to accelerate and simplify access to cloud solutions.
  • Having many years of experience in providing security solutions to many international markets, MONITORAPP offers versatile security solutions for businesses through physical and virtual appliances, as well as the comprehensive cloud-based SECaaS platform AIONCLOUD.
  • Starting with ‘Cloud Security Setting Diagnosis Service’, it has recently focused on the ‘Managed Cloud & Security Service Provider’ (MCSSP) business.
  • Both companies plan to engage in business cooperation, joint marketing, collaborative research, employee exchange, and personal development.

Harbour BioMed Reports Full Year 2023 Financial Results

Retrieved on: 
Donnerstag, März 28, 2024

We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

Key Points: 
  • We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
  • Harbour BioMed recorded the profit of US$22.8 million for the year ended 31 December 2023.
  • This is the first time that the Company has recorded a net profit on its annual financial statements.
  • Looking to the future, Harbour BioMed will keep driving business growth and accomplishing its mission through two key pillars, Harbour Therapeutics and Nona Biosciences.

Comerica Bank Reveals Largest, State-of-the-Art Comerica CoWorkSpaces™ at The Star in Frisco

Retrieved on: 
Donnerstag, März 14, 2024

DALLAS, March 14, 2024 /PRNewswire/ -- Comerica Bank today unveiled a distinctive feature component of its new Frisco Business & Innovation Hub. The bank's newest and largest Comerica CoWorkSpaces™ location in North Texas anchors the entire first floor of the office tower at 17 Cowboys Way at The Star in Frisco.

Key Points: 
  • DALLAS, March 14, 2024 /PRNewswire/ -- Comerica Bank today unveiled a distinctive feature component of its new Frisco Business & Innovation Hub.
  • The bank's newest and largest Comerica CoWorkSpaces™ location in North Texas anchors the entire first floor of the office tower at 17 Cowboys Way at The Star in Frisco.
  • "The Comerica CoWorkSpaces program has made a tremendous impact for our small business customers in the Collin and Denton County footprints," said Jim Weber, Comerica Bank Chief Experience Officer.
  • CoWorkSpaces directly addresses these needs and delivers a value-added experience at no cost to Comerica small business customers.

Bottomline Unveils Enhanced Internal Threat Management Solution

Retrieved on: 
Donnerstag, Februar 22, 2024

The enhanced solution supports organizations to better use data visualizations, threat profiles and advanced case management strategies in fighting insider fraud.

Key Points: 
  • The enhanced solution supports organizations to better use data visualizations, threat profiles and advanced case management strategies in fighting insider fraud.
  • Already making headlines, Bottomline’s Internal Threat Management Solution (ITM) was recently named the market leader in Quadrant Knowledge Solution’s 2023 Spark Matrix™ for Insider Risk Management.
  • Our newly enhanced Insider Threat Management solution brings this reality to the forefront.
  • Whether an internal threat is malicious or unintentional, the technology visually maps connections between unusual activities and users, expediting the detection of insider activity, including external fraud initiated from within.

Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development

Retrieved on: 
Dienstag, Februar 27, 2024

The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.

Key Points: 
  • The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.
  • Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed, "By leveraging our accumulated knowledge of ADC discovery and utilizing our advanced therapeutic antibody platforms validated by partners worldwide, this collaboration will expedite the development of first-in-class ADCs targeting cancer.
  • Gwanghee Lee, Founder and CEO of Boostimmune, stated, "We are excited to collaborate with Nona Biosciences.
  • Through this collaboration, we are confident in making significant strides in addressing the unmet needs of cancer patients."

ITM Obtains Manufacturing License in the U.S.

Retrieved on: 
Donnerstag, Februar 1, 2024

Obtaining the wholesale license is a pivotal requirement for ITM’s business activities in the United States.

Key Points: 
  • Obtaining the wholesale license is a pivotal requirement for ITM’s business activities in the United States.
  • Upon opening its new offices, the company prepared for potential market registration of its targeted radiopharmaceutical pipeline product candidates and filed for obtaining the wholesale license.
  • After an inspection from regulatory bodies that found no deficiencies, the wholesale license was issued to ITM on January 16, 2024.
  • “Obtaining the wholesale license is a crucial step in expanding our U.S. business as we prepare for the future launch of both our diagnostic and therapeutic radiopharmaceutical products in this important geography,” commented Steffen Schuster, CEO of ITM.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

Retrieved on: 
Dienstag, Januar 30, 2024

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.

Key Points: 
  • GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.
  • Under the terms of the agreement, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a.
  • 177Lu for the clinical development of Alpha-9 radiopharmaceutical candidates comprising n.c.a.
  • ITM holds a U.S. Drug Master File (DMF) with the Food and Drug Administration (FDA) for n.c.a.

IncredibleBank Opens Branch in Cape Coral, FL

Retrieved on: 
Freitag, Januar 26, 2024

This branch, located at 2512 Skyline Boulevard in Cape Coral, is their first location outside of Wisconsin and Michigan’s Upper Peninsula.

Key Points: 
  • This branch, located at 2512 Skyline Boulevard in Cape Coral, is their first location outside of Wisconsin and Michigan’s Upper Peninsula.
  • “While our branch is only just opening its doors, we have been integrating ourselves in the Cape Coral community over the last year plus,” said Todd Nagel, President and Chief Executive Officer of IncredibleBank.
  • The pickup boxes will allow customers to order items in advance and pick them up securely, even after hours.
  • The space in the branch is thoughtfully designed to invite collaboration, comfort, and privacy.